Capricor Therapeutics
Develops deramiocel for Duchenne muscular dystrophy and StealthX exosome therapies.
Something off on this page? Send us feedback.
Profile
Develops cell and exosome-based therapies, led by deramiocel for Duchenne muscular dystrophy and the StealthX platform. Product sales are still pre-commercial; the business depends on FDA review, manufacturing execution, and Nippon Shinyaku distribution arrangements in the United States and Japan.
Develops deramiocel, an allogeneic cell therapy made from cardiosphere-derived cells, for Duchenne muscular dystrophy. The broader pipeline includes StealthX, an engineered-exosome platform for vaccines and therapeutic delivery.
Execution centers on clinical development, regulatory approval work, and manufacturing responsibility from a San Diego base, with one reportable segment focused on therapeutic-candidate development and commercialization. The strategy reflects a pivot from earlier heart-disease programs toward DMD and exosome research.
Product sales have not begun because deramiocel and StealthX remain investigational. Regulatory review, manufacturing responsibility, and the Nippon Shinyaku distribution arrangements for the United States and Japan shape the near-term business structure.
Company facts
Key statistics
Year to date −66.1% · Average volume (30d) 10.7M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Aug 25, 2026 | Oppenheimer | Upgrade | Perform | Outperform | ||
| Aug 14, 2026 | Cantor Fitzgerald | Upgrade | Neutral | Overweight | ||
| Aug 13, 2026 | Cantor Fitzgerald | Upgrade | Neutral | Overweight | ||
| Jul 31, 2026 | Jones Trading | Downgrade | Buy | Hold | ||
| Jul 30, 2026 | Oppenheimer | Downgrade | Outperform | Perform |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 14, 2026Q2 FY26 | −$0.59 | −$0.70 | −18.9% | $2.1M | — | — | +12.03% |
| Aug 13, 2026Q2 FY26 | −$0.59 | −$0.70 | −18.9% | $2.1M | — | — | +57.96% |
| May 12, 2026Q1 FY26 | −$0.55 | −$0.59 | −7.3% | $40.0M | — | — | −3.78% |
| Mar 12, 2026Q4 FY25 | −$0.51 | −$0.62 | −21.6% | $525.0K | — | — | −8.74% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | |
| Gross profit | −$18.9M | −$22.0M | −$20.4M | $0 | $0 | $0 | |
| Operating income | −$25.0M | −$27.7M | −$26.3M | −$29.2M | −$36.8M | −$42.9M | |
| Net income | −$24.4M | −$25.9M | −$24.6M | −$30.2M | −$33.9M | −$40.7M | |
| Diluted EPS | −$0.53 | −$0.57 | −$0.54 | −$0.62 | −$0.59 | −$0.70 | |
| Gross margin | — | — | — | — | — | — | |
| Operating margin | — | — | — | — | — | — |
Fiscal years (4-quarter sums)FY21 $244.9K · FY22 $2.6M · FY23 $25.2M · FY24 $22.3M · FY25 $0
Balance sheet, Jun 30, 2026Cash & short-term investments $237.9M · Total debt $91.0M · Total assets $368.7M · Shareholders' equity $246.2M
Dividends
No dividends on record.
Ownership
Shares outstanding 57.51M · Float 48.21M · 83.8% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Suvretta Capital Management, LLC | 3.82M | 6.64% | 13F | May 15, 2026 |
| BlackRock, Inc. | 3.42M | 5.95% | 13F | May 13, 2026 |
| Tang Capital Management LLC | 3.40M | 5.91% | 13F | May 15, 2026 |
| RA Capital Management, L.P. | 3.01M | 5.20% | 13G | Aug 3, 2026 |
| State Street Corp | 2.18M | 3.79% | 13F | May 15, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 25, 2026 | Anthony Bergmann | officer: CHIEF FINANCIAL OFFICER | −24,100 | $30.38 |
| Jun 25, 2026 | Karen Krasney | officer: EVP, GENERAL COUNSEL | −24,100 | $30.38 |
| Jun 24, 2026 | Anthony Bergmann | officer: CHIEF FINANCIAL OFFICER | −400 | $30.00 |
| Jun 24, 2026 | Karen Krasney | officer: EVP, GENERAL COUNSEL | −400 | $30.00 |
| May 1, 2026 | Anthony Bergmann | officer: CHIEF FINANCIAL OFFICER | −25,000 | $31.70 |
Peers
- Sarepta Therapeutics
Dominant approved DMD portfolio across exon skipping and gene therapy
- Dyne Therapeutics
Late-stage exon 51 DMD RNA therapy challenger
- REGENXBIO
Late-stage microdystrophin gene-therapy competitor
- Solid Biosciences
Phase 3 Duchenne gene therapy with cardiac-muscle emphasis
- Novartis (ADR)
Avidity-derived DMD44 RNA program inside a traded ADR
- Edgewise Therapeutics
Transitional sevasemten owner in DMD muscle protection
- PTC Therapeutics
Commercial DMD drugs with narrower current overlap
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Capricor Therapeutics | $9.64 | +0.41% | $551.5M | — | — | — | — |
| Sarepta Therapeutics | $21.05 | +0.98% | $2.20B | — | 26.3 | 1.1 | −34.3% |
| Dyne Therapeutics | $25.07 | −0.04% | $4.68B | — | — | — | — |
| REGENXBIO | $9.65 | −0.21% | $499.4M | — | — | 2.9 | +405.7% |
| Solid Biosciences | $9.77 | −0.10% | $961.9M | — | — | — | — |
| Novartis (ADR) | $153.81 | 0.00% | $292.35B | 23.2 | 16.4 | 5.3 | +0.9% |
| Edgewise Therapeutics | $42.76 | −0.04% | $4.60B | — | — | — | — |
| PTC Therapeutics | $70.59 | +0.73% | $5.85B | — | 58.0 | 5.8 | +101.6% |
| Median | 23.2 | 26.3 | 4.1 | +51.2% |